
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Loading…
Data from Twelve Data. Prices may be delayed.
No analyst coverage available.
FOMC Minutes
2:00 PM ET
Initial Jobless Claims
8:30 AM ET

Bitcoin (BTC)
63,179 −0.72%

Ethereum (ETH)
1,771 −0.77%

Solana (SOL)
74 +2.41%

Corporate PresentationOct 7, 2026
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Generated by AI